Drug Therapy

Elias S. Siraj, MD
Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic

Address: Elias S. Siraj, MD, Department of Endocrinology, Diabetes and Metabolism, A53, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

This article discusses therapies that are not approved by the US Food and Drug Administration.

Elias S. Siraj, MD
Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic

Address: Elias S. Siraj, MD, Department of Endocrinology, Diabetes and Metabolism, A53, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

This article discusses therapies that are not approved by the US Food and Drug Administration.

Elias S. Siraj, MD
Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic

Address: Elias S. Siraj, MD, Department of Endocrinology, Diabetes and Metabolism, A53, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

This article discusses therapies that are not approved by the US Food and Drug Administration.

Rashmi Deshmukh, MD
Department of Psychiatry and Psychology, The Cleveland Clinic

Kathleen Franco, MD
Head, Section of Consultation-Liaison, Psychiatry, Department of Psychiatry and Psychology, The Cleveland Clinic

Address: Kathleen Franco, MD, Section of Consultation-Liaison Psychiatry, Department of Psychiatry and Psychology, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Franco has indicated that she is on the speakers’ bureau of the Pfizer company.

Rashmi Deshmukh, MD
Department of Psychiatry and Psychology, The Cleveland Clinic

Kathleen Franco, MD
Head, Section of Consultation-Liaison, Psychiatry, Department of Psychiatry and Psychology, The Cleveland Clinic

Address: Kathleen Franco, MD, Section of Consultation-Liaison Psychiatry, Department of Psychiatry and Psychology, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Franco has indicated that she is on the speakers’ bureau of the Pfizer company.

Rashmi Deshmukh, MD
Department of Psychiatry and Psychology, The Cleveland Clinic

Kathleen Franco, MD
Head, Section of Consultation-Liaison, Psychiatry, Department of Psychiatry and Psychology, The Cleveland Clinic

Address: Kathleen Franco, MD, Section of Consultation-Liaison Psychiatry, Department of Psychiatry and Psychology, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Franco has indicated that she is on the speakers’ bureau of the Pfizer company.

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Chad Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic

James Gideon, MD, PhD
Blanchard Valley Medical Associates, Findlay, OH

Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.

Mina K. Chung, MD
Section of Cardiac Electrophysiology, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Mina K. Chung, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Mina K. Chung, MD
Section of Cardiac Electrophysiology, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Mina K. Chung, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Mina K. Chung, MD
Section of Cardiac Electrophysiology, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Mina K. Chung, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.